No statistically significant differences in efficacy and safety were seen between vedolizumab and certolizumab pegol for the treatment of Crohn’s disease, a study published inPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy has found.
Researchers from Poland aimed to compare the efficacy and safety of vedolizumab and certolizumab pegol in patients with active moderate-to-severe Crohn’s disease. They conducted a systematic literature search of Medline, Embase, and the Cochrane Library through March 5, 2016. The studies for inclusion were randomized-controlled trials that enrolled patients for treatment of Crohn’s disease with vedolizumab or certolizumab pegol.
A total of eight randomized-controlled trials were identified, of which four qualified for inclusion in the indirect comparison of the induction phase of treatment. Study authors found no statistically significant differences in clinical response (risk ratio [RR] 1.23, 95% CI: 0.81–1.88) or remission (RR 1.35, 95% CI: 0.89–2.07) between vedolizumab and certolizumab pegol in the overall population.
In a sub-group analysis of anti-TNF-naive patients, non-statistically significant differences in response and remission were also observed (RR 1.10, 95% CI: 0.72–1.66 and RR 1.98, 95% CI: 0.95–4.11, respectively). Similarly, no statistically significant differences in safety profiles were noted between the two treatments.
For more information visit onlinelibrary.wiley.com.